Equillium, Inc. current report, 14 December 2022

Full document

Equillium, Inc. Form 8-K Summary

Business context and reporting period

Filed December 14, 2022 under Item 8.01, this report supplements Equillium’s and Metacrine, Inc.’s joint proxy statement/prospectus for their proposed all-stock merger. It does not provide a quarterly or annual earnings update. The supplemental disclosures respond to stockholder demands and three lawsuits alleging inadequate merger-related disclosures.

Equillium and Metacrine deny the allegations and state that the original disclosures complied with applicable law. They voluntarily provided additional information to address disclosure claims, avoid potential expense and delays, and provide further information to stockholders.

Financial metrics and transaction-related analyses

  • The filing does not provide current revenue, net income, operating cash flow, margins, or liquidity balances for Equillium for the reporting period.
  • In the merger analyses, Equillium was described as having cash of $57.6 million and debt of $10.3 million, with no preferred stock or minority interest, based on information used in the fairness analyses.
  • Equillium’s revised February 17, 2022 proposal valued Metacrine at approximately $28 million and the post-closing combined company at approximately $144 million. It included potential cash contingent value rights, or CVRs, of up to $272.5 million tied to MET642 milestones.
  • Equillium’s March 2, 2022 best-and-final proposal valued Metacrine at $37.5 million and included potential CVRs of up to $22.5 million tied to MET642 milestones.
  • Projected Equillium unlevered free cash flow in one analysis was negative through 2026, turning positive at approximately $4 million in 2027 and reaching approximately $160 million in 2038. A separate October-projection analysis showed negative free cash flow through 2027, positive free cash flow of approximately $49 million in 2028, and approximately $424 million in 2038. These are valuation projections, not reported results or company guidance.
  • The October-projection DCF used a combined-company weighted average cost of capital sensitivity range of 14.0% to 18.0% and assumed no terminal value.
  • One revised comparable-company analysis produced an implied Equillium equity value range of $105 million to $160 million and an implied share-price range of $3.10 to $4.65. The filing states that the correction did not change MTS’s fairness conclusion.
  • The revised pro forma analysis showed a Metacrine per-share value range of $6.30 to $12.70, based on a low-end exchange ratio of 0.282x and sensitivity to cumulative acute graft-versus-host disease probability of success and combined-company WACC.

Material changes versus prior disclosure

  • The filing revises the background of the merger to describe earlier Equillium proposals, their valuation terms, proposed board treatment, and CVR provisions.
  • It replaces portions of the PIPE transaction analysis, including the transaction sample sizes and premium-plus-fee statistics for 2021, 2022, and all transactions up to $100 million.
  • It clarifies that Metacrine’s liquidation analysis assigned meaningful value primarily to net cash because Metacrine was not expected to generate revenue and its net cash was insufficient to support it as a standalone company.
  • It updates the DCF projections, comparable-company sets, valuation dates, enterprise-value adjustments, and pro forma analyses used by MTS Health Partners, L.P. in its fairness-related work.
  • The filing corrects the use of market capitalization rather than enterprise value for Akari Therapeutics and X4 Pharmaceuticals in one comparable-company analysis. MTS stated that the correction did not alter its fairness conclusion.

Outlook, risks, contingencies, and unusual items

  • The proposed merger remained subject to shareholder approvals, satisfaction or waiver of closing conditions, and other customary requirements. The filing does not state that the merger had closed.
  • Key transaction risks include delays or failure to consummate the merger, failure to obtain shareholder approval, inability to realize anticipated benefits, and difficulty executing the combined company’s plans.
  • The litigation and stockholder demands could create legal expense, management distraction, business delays, or additional disclosure obligations, although the filing does not quantify any potential cost or liability.
  • Projected synergies differed between analyses: one pro forma analysis included projected general and administrative savings beginning at $15 million in 2022E and generally $3 million annually after 2026, while a later analysis assumed $0 of projected synergies.
  • The filing emphasizes that forward-looking projections, valuation assumptions, milestone-based CVRs, merger benefits, and clinical development expectations are subject to substantial uncertainty and should not be treated as guarantees.

Important facts for investors to verify

  1. Whether the merger received all required shareholder and regulatory approvals and ultimately closed.
  2. The definitive exchange ratio, share issuance, dilution, and any applicable exchange-ratio collar.
  3. The actual cash, debt, operating runway, and financing requirements of Equillium and the combined company.
  4. The status, valuation, and payment conditions of the MET642-related CVRs and any other contingent consideration.
  5. The status and resolution of the three disclosed lawsuits and related stockholder demands.
  6. Whether the long-term DCF assumptions, including clinical probability of success, timing of profitability, WACC, and projected synergies, remain reasonable.
  7. The underlying joint proxy statement/prospectus, merger agreement, fairness opinions, and subsequent SEC filings for final transaction terms and updated risk disclosures.